KYTX

Kyverna Therapeutics Inc

5.05

Nov 13 • 3:59 PM ET +0.02 (0.40%)

5.08

Aftermarket • 7:16 PM ET +0.03 (0.60%)

Healthcare Biotechnology USA Small NASD

Nov 12, 11:46 AMKyverna completed its BLA submission for miv-cel in stiff person syndrome, seeking FDA priority review.

Peers: CABA RNAC ARTV AUTL SANA FATE ALLO NKTX ARGX IMVT

| Held by: VTI IWM VXF FESM IWN VTWO IBB KOMP SCHA SURI

Scroll to Statements

Index	RUT
Market Cap	319.27M
Enterprise Value	181.15M
Income	-157.79M
Sales	0.00M
Book/sh	2.13
Cash/sh	2.70
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	130
IPO	Feb 08, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.37
P/C	1.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.01
Current Ratio	7.01
Debt/Eq	0.24
LT Debt/Eq	0.23
Option/Short	Yes / Yes

EPS (ttm)	-2.77
EPS next Y	-2.97
EPS next Q	-0.74
EPS this Y	25.98%
EPS next Y	-10.25%
EPS next 5Y	10.80%
EPS past 3/5Y	-75.86% -56.27%
Sales past 3/5Y	- -
EPS Y/Y TTM	25.69%
Sales Y/Y TTM	-
EPS Q/Q	20.11%
Sales Q/Q	-
Earnings	Nov 12 BMO
EPS/Sales Surpr.	1.63% -

Insider Own	37.02%
Insider Trans	0.00%
Inst Own	50.93%
Inst Trans	2.88%
ROA	-83.80%
ROE	-110.69%
ROIC	-96.04%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.15%
SMA50	-18.77%
SMA200	-35.98%
Trades

Shs Outstand	62.54M
Shs Float	38.95M
Short Float	23.35%
Short Ratio	10.59
Short Interest	9.10M
52W High	13.67 -63.06%
52W Low	4.49 12.35%
Volatility	9.01% 7.98%
ATR (14)	0.43
RSI (14)	39.05
Beta	2.15
Rel Volume	0.97
Avg Volume	858.86K
Volume	834,292

Perf Week	3.48%
Perf Month	-15.41%
Perf Quarter	-43.58%
Perf Half Y	-46.79%
Perf YTD	-46.28%
Perf Year	-22.07%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	30.40
Prev Close	5.03
Price	5.05
Change %	0.40%

Consensus

Strong Buy

Avg. Price Target

$30.40

Implied Upside

+502.0%

Analysts8incl. previous ratings

Rating Distribution8 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 20, 2025	Initiated	WWilliam Blair	Outperform
May 27, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$5	-1.0%
Oct 10, 2024	Initiated	UUBS	Buy	$13	+157.4%
Oct 09, 2024	Initiated	RRodman & Renshaw	Buy	$16	+216.8%
Jul 03, 2024	Initiated	HH.C. Wainwright	Neutral	$8	+58.4%
Mar 04, 2024	Initiated	WWells Fargo	Overweight	$44	+771.3%
Mar 04, 2024	Initiated	MMorgan Stanley	Overweight	$40	+692.1%
Mar 04, 2024	Initiated	LLeerink Partners	Outperform	$48	+850.5%
Mar 04, 2024	Initiated	JJP Morgan	Overweight	$39	+672.3%

Nov-12-26 12:12PM	Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
08:00AM	Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Nov-09-26 11:00AM	Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology (GlobeNewswire) +5.94%
Nov-05-26 04:02PM	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -10.66% +5.86%
Oct-23-26 10:30AM	Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 (GlobeNewswire) -5.93%
02:20PM	Loading…
Oct-22-26 02:20PM	Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
Oct-21-26 07:15AM	Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto (GlobeNewswire)
Oct-07-26 08:00AM	Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 (GlobeNewswire)
Sep-24-26 02:28PM	KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data But CEO Says Disease Burden Justifies A Premium Price (Stocktwits)
10:05AM	Kyverna stock jumps on positive one-year therapy data (Investing.com)
06:39AM	Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials (InvestorsHub)
06:00AM	Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis (GlobeNewswire)
Sep-02-26 04:05PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
Aug-11-26 04:02PM	Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results (GlobeNewswire)
08:00AM	Loading…
Jul-27-26 08:00AM	Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel (GlobeNewswire) +6.88%
Jun-22-26 08:00AM	Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition (GlobeNewswire)
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge)
Jun-03-26 08:00AM	Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis (GlobeNewswire)
May-18-26 08:00AM	Kyverna Therapeutics Names Greg Martini as Chief Financial Officer (GlobeNewswire) -10.01%
May-14-26 08:00AM	Kyverna Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-13-26 06:27AM	Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B (BioPharma Dive) +5.38%
May-12-26 04:02PM	Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-04-26 08:00AM	Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer (GlobeNewswire)
Apr-21-26 06:45PM	Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting (GlobeNewswire) -13.69% +5.36%
Apr-20-26 08:00AM	Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks (GlobeNewswire) +13.29%
Apr-09-26 08:00AM	Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026 (GlobeNewswire)
Mar-26-26 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-05-26 04:21PM	Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 (GlobeNewswire) -5.41%
Mar-03-26 08:00AM	Kyverna Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire) -5.76%
08:00AM	Loading…
Feb-24-26 08:00AM	Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-03-26 08:00AM	Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer (GlobeNewswire)
Jan-12-26 08:00AM	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -7.30%
Dec-30-25 07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-17-25 09:24AM	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock (GlobeNewswire) -32.52%
Dec-16-25 10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks) -5.36%
09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.23%
06:30AM	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (GlobeNewswire)
03:41AM	Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease (BioPharma Dive)
Dec-14-25 02:30PM	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome (GlobeNewswire)
Dec-12-25 07:30AM	2 Strong Buy Biotech Stocks With 208% to 329% Upside Potential (Barchart) +5.02%
Nov-12-25 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.60%
Nov-10-25 08:00AM	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-03-25 08:00AM	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance (GlobeNewswire)
Oct-29-25 06:30AM	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 (GlobeNewswire) -5.78%
Oct-25-25 11:00AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 (GlobeNewswire)
Oct-22-25 08:00AM	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis (GlobeNewswire) -6.58%
Oct-17-25 09:59AM	Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout (Insider Monkey) -5.42%
Sep-24-25 09:05AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS (GlobeNewswire)
Sep-15-25 01:02PM	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (GlobeNewswire)
Aug-28-25 08:00AM	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event (GlobeNewswire)
Aug-25-25 04:02PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire) +14.90%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:23AM	Kyverna Appoints New CFO to Guide Next Growth Phase (Insider Monkey) -11.09%
08:30AM	Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise (PR Newswire)
Jun-30-25 09:00AM	Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KAREN WALKER	Officer	Apr 17 '26	Proposed Sale	9.53	10,000	95,300		Apr 17 04:37 PM
KAREN WALKER	Officer	Apr 14 '26	Proposed Sale	9.49	2,459	23,336		Apr 14 04:38 PM
DANIEL SPIEGELMAN	Director	Apr 07 '26	Proposed Sale	9.25	17,578	162,637		Apr 07 04:05 PM
DANIEL SPIEGELMAN	Director	Mar 31 '26	Proposed Sale	8.44	16,634	140,404		Mar 31 05:09 PM
SEIDENBERG BETH C	Director	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:43 AM
Westlake BioPartners Opportuni	10% Owner	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:42 AM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Option Exercise	4.83	23,998	115,910	46,634	Dec 17 08:30 PM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Sale	12.20	23,998	292,776	22,636	Dec 17 08:30 PM
KAREN WALKER	Officer	Dec 15 '25	Proposed Sale	8.78	23,998	210,702		Dec 15 04:16 PM

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Executive ChairpersonMs. Christi L. Shaw

CEO & DirectorMr. Warner Biddle

M.D.Dr. Naji H. Gehchan M.B.A.

Chief Financial OfficerMr. Gregory Martini

Senior VP & Head of ResearchDr. Tom Van Blarcom Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

KYTX

Kyverna Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.